A detailed history of Tower Research Capital LLC (Trc) transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,875 shares of IKNA stock, worth $2,943. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,875
Previous 20,132 90.69%
Holding current value
$2,943
Previous $33,000 90.91%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.6 - $1.85 $29,211 - $33,775
-18,257 Reduced 90.69%
1,875 $3,000
Q2 2024

Aug 13, 2024

BUY
$1.24 - $1.82 $13,892 - $20,391
11,204 Added 125.49%
20,132 $33,000
Q1 2024

May 15, 2024

BUY
$1.27 - $2.0 $4,994 - $7,866
3,933 Added 78.74%
8,928 $12,000
Q4 2023

Feb 13, 2024

BUY
$1.33 - $4.4 $1,705 - $5,640
1,282 Added 34.53%
4,995 $9,000
Q3 2023

Nov 14, 2023

BUY
$4.09 - $6.43 $11,439 - $17,984
2,797 Added 305.35%
3,713 $16,000
Q2 2023

Aug 14, 2023

SELL
$3.5 - $7.31 $9,264 - $19,349
-2,647 Reduced 74.29%
916 $6,000
Q1 2023

May 09, 2023

SELL
$2.62 - $4.97 $27,130 - $51,464
-10,355 Reduced 74.4%
3,563 $13,000
Q4 2022

Feb 10, 2023

BUY
$2.0 - $3.7 $20,152 - $37,281
10,076 Added 262.26%
13,918 $37,000
Q3 2022

Nov 10, 2022

BUY
$3.46 - $6.0 $2,349 - $4,074
679 Added 21.47%
3,842 $13,000
Q2 2022

Aug 15, 2022

BUY
$3.23 - $7.4 $4,392 - $10,064
1,360 Added 75.43%
3,163 $14,000
Q1 2022

May 12, 2022

BUY
$5.61 - $13.85 $269 - $664
48 Added 2.74%
1,803 $11,000
Q4 2021

Feb 14, 2022

BUY
$10.52 - $16.96 $10,614 - $17,112
1,009 Added 135.25%
1,755 $22,000
Q3 2021

Nov 15, 2021

SELL
$9.82 - $15.23 $4,733 - $7,340
-482 Reduced 39.25%
746 $9,000
Q2 2021

Aug 16, 2021

BUY
$13.27 - $26.0 $16,295 - $31,928
1,228 New
1,228 $17,000

Others Institutions Holding IKNA

About Ikena Oncology, Inc.


  • Ticker IKNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,257,500
  • Market Cap $56.9M
  • Description
  • Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...
More about IKNA
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.